A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Universitätsklinikum Hamburg-Eppendorf
Pfizer
Alliance for Clinical Trials in Oncology
Institute of Hematology & Blood Diseases Hospital, China
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Sanofi
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
Gilead Sciences
University of Maryland, Baltimore
Therapeutic Advances in Childhood Leukemia Consortium
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
Celgene
St. Jude Children's Research Hospital
Children's Oncology Group
Children's Oncology Group
Alliance for Clinical Trials in Oncology
Barbara Ann Karmanos Cancer Institute
Children's Oncology Group
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Children's Oncology Group
Children's Oncology Group
Rutgers, The State University of New Jersey
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)